BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32500598)

  • 1. Metastatic patterns do not provide additional prognostic information for patients with FIGO stage IV high-grade serous ovarian cancer.
    Feng Z; Wen H; Ju X; Bi R; Chen X; Yang W; Wu X
    J Surg Oncol; 2020 Aug; 122(2):315-319. PubMed ID: 32500598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. International Federation of gynecology and obstetrics staging classification for cancer of the ovary, fallopian tube, and peritoneum: estimation of survival in patients with node-positive epithelial ovarian cancer.
    Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Peregrin I; Mendizabal E; Ortiz-Quintana L
    Int J Gynecol Cancer; 2015 Jan; 25(1):49-54. PubMed ID: 25405578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Suggested Modification to FIGO Stage IV Epithelial Ovarian Cancer.
    Métairie M; Benoit L; Koual M; Bentivegna E; Wohrer H; Bolze PA; Kerbage Y; Raimond E; Akladios C; Carcopino X; Canlorbe G; Uzan J; Lavoué V; Mimoun C; Huchon C; Koskas M; Costaz H; Margueritte F; Dabi Y; Touboul C; Bendifallah S; Ouldamer L; Delanoy N; Nguyen-Xuan HT; Bats AS; Azaïs H
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of the subclassification of Müllerian cancer stage IV in the FIGO 2014 staging system with a focus of extra-abdominal lymph node metastases.
    Yasunaga M; Yahata H; Okugawa K; Hori E; Kodama K; Yagi H; Ohgami T; Onoyama I; Asanoma K; Kato K
    Int J Clin Oncol; 2021 Jul; 26(7):1330-1335. PubMed ID: 33786711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer.
    Zeppernick F; Meinhold-Heerlein I
    Arch Gynecol Obstet; 2014 Nov; 290(5):839-42. PubMed ID: 25082067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective analysis for investigating the relationship between FIGO stage IVA/IVB and cytoreductive surgery with prognosis in epithelial ovarian cancer.
    Liu H; Luo M; Peng C; Huang J; Wang D; Huang J; Zhang G
    Front Oncol; 2023; 13():1103357. PubMed ID: 37564940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of Revised FIGO Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum Based on a Single Histological Type.
    Toptas T; Pestereli E; Erol O; Bozkurt S; Erdogan G; Simsek T
    Int J Gynecol Cancer; 2016 Jul; 26(6):1012-9. PubMed ID: 27206284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
    Gasimli K; Braicu EI; Nassir M; Richter R; Babayeva A; Chekerov R; Darb-Esfahani S; Sehouli J; Muallem MZ
    Ann Surg Oncol; 2016 Apr; 23(4):1279-86. PubMed ID: 26832880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The FIGO Stage IVA Versus IVB of Ovarian Cancer: Prognostic Value and Predictive Value for Neoadjuvant Chemotherapy.
    Tajik P; van de Vrie R; Zafarmand MH; Coens C; Buist MR; Vergote I; Bossuyt PMM; Kenter GG
    Int J Gynecol Cancer; 2018 Mar; 28(3):453-458. PubMed ID: 29324537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymph node metastases as only qualifier for stage IV serous ovarian cancer confers longer survival than other sites of distant disease - a Swedish Gynecologic Cancer Group (SweGCG) study.
    Hjerpe E; Staf C; Dahm-Kähler P; Stålberg K; Bjurberg M; Holmberg E; Borgfeldt C; Tholander B; Hellman K; Kjølhede P; Högberg T; Rosenberg P; Åvall-Lundqvist E
    Acta Oncol; 2018 Mar; 57(3):331-337. PubMed ID: 29130381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors and the role of primary debulking in operable stage IVB ovarian cancer with supraclavicular lymph node metastasis: a retrospective study in Chinese patients.
    Quan C; Chen X; Wen H; Wu X; Li J
    BMC Cancer; 2024 May; 24(1):565. PubMed ID: 38711015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients.
    Feng Z; Wen H; Bi R; Duan Y; Yang W; Wu X
    BMC Cancer; 2016 Jan; 16():43. PubMed ID: 26817451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restaging and Survival Analysis of 4036 Ovarian Cancer Patients According to the 2013 FIGO Classification for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.
    Rosendahl M; Høgdall CK; Mosgaard BJ
    Int J Gynecol Cancer; 2016 May; 26(4):680-7. PubMed ID: 26937751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of lymph node ratio on survival in stage III ovarian high-grade serous cancer: a Turkish Gynecologic Oncology Group study.
    Ayhan A; Ozkan NT; Sarı ME; Celik H; Dede M; Akbayır Ö; Güngördük K; Şahin H; Haberal A; Güngör T; Arvas M; Meydanlı MM
    J Gynecol Oncol; 2018 Jan; 29(1):e12. PubMed ID: 29185270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of clinical behavior between mucinous ovarian carcinoma with infiltrative and expansile invasion and high-grade serous ovarian carcinoma: a retrospective analysis.
    Hada T; Miyamoto M; Ishibashi H; Matsuura H; Kakimoto S; Iwahashi H; Tsuda H; Takano M
    Diagn Pathol; 2022 Jan; 17(1):12. PubMed ID: 35057833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. THE PROGNOSTIC SIGNIFICANCE OF P53, BCL2 AND MIB1 EXPRESSIONS RELATED WITH OTHER CLINICOPATHOLOGICAL VARIABLES IN SEROUS OVARIAN CARCINOMAS. A CLINICOPATHOLOGICAL STUDY IN PERITONEAL FLUIDS.
    Kalogeraki A; Tamiolakis D; Matalliotaki C; Karvela-Kalogeraki I; Karvelas-Kalogerakis M; Segredakis J; Sinatkas V; Matalliotakis I
    Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):454-60. PubMed ID: 26204652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subtypes of stage IV ovarian cancer; response to treatment and patterns of disease recurrence.
    Jamieson A; Sykes P; Eva L; Bergzoll C; Simcock B
    Gynecol Oncol; 2017 Aug; 146(2):273-278. PubMed ID: 28549816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The preoperative prognostic nutritional index is a predictive and prognostic factor of high-grade serous ovarian cancer.
    Feng Z; Wen H; Ju X; Bi R; Chen X; Yang W; Wu X
    BMC Cancer; 2018 Sep; 18(1):883. PubMed ID: 30200903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of supradiaphragmatic lymph nodes at initial presentation in patients with stage III high-grade serous ovarian cancer.
    McIntosh LJ; O'Neill AC; Bhanusupriya S; Matalon SA; Van den Abbeele AD; Ramaiya NH; Shinagare AB
    Abdom Radiol (NY); 2017 Oct; 42(10):2513-2520. PubMed ID: 28429056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors.
    Shih KK; Zhou QC; Aghajanian C; Huh J; Soslow RA; Morgan JC; Iasonos A; Chi DS; Barakat RR; Abu-Rustum NR
    Gynecol Oncol; 2010 Nov; 119(2):270-3. PubMed ID: 20719369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.